AVI looks to take eteplirsen forward on back of positive Phase IIb data for DMD
This article was originally published in Scrip
Executive Summary
AVI BioPharma is ready to confirm the long-term effectiveness of its RNA-based therapeutic eteplirsen now that it has 24-week data in hand showing that the drug met the primary efficacy endpoint in a Phase IIb clinical trial by producing the essential protein needed by patients with the rare disease Duchenne muscular dystrophy (DMD).